ArticleCureus2026
Etiological Spectrum of Hypercalcemia in a North Indian Tertiary Care Center: Emerging Role of Vitamin D Toxicity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlobally, primary hyperparathyroidism and malignancy account for the majority of hypercalcemia cases. However, regional epidemiological variations exist. Kashmir, a high-altitude region in North India with a high prevalence of vitamin D deficiency, has witnessed increasing use of high-dose vitamin D supplementation. This has led to growing concern about iatrogenic hypercalcemia secondary to hypervitaminosis D. This study aimed to evaluate the current etiological spectrum of hypercalcemia among hospitalized patients in Kashmir and to assess the contribution of vitamin D toxicity and its underlying causes. MATERIALS AND
methodsThis retrospective study included adult patients (≥18 years) admitted to a tertiary care center in Kashmir between 1 January 2025 and 30 June 2025 with corrected serum calcium >10.5 mg/dL on at least two occasions. Demographic data, biochemical parameters, and etiological diagnoses were retrieved from hospital records. Data were analyzed using descriptive statistics, and comparisons between groups were performed using the Student's t-test, Mann-Whitney U test, and chi-square test.
resultsA total of 40 patients were included (mean age 62 ± 12.8 years; 52.5% female). Malignancy (including multiple myeloma and lymphoma) was the most common cause of hypercalcemia, followed by primary hyperparathyroidism (20%) and vitamin D toxicity (20%). Patients with hypervitaminosis D had markedly elevated 25-hydroxyvitamin D levels (123.5 ± 25 ng/mL) with suppressed intact parathyroid hormone (iPTH) levels. Patients with malignancy-associated hypercalcemia were significantly older than those with non-malignant causes, whereas serum 25-hydroxyvitamin D levels and iPTH were significantly higher in the non-malignant group. Review of prior regional studies demonstrated frequent administration of high-dose intramuscular cholecalciferol (600,000 IU) and repeated high-dose oral supplementation as major contributors to toxicity.
conclusionsWhile malignancy and primary hyperparathyroidism remain leading causes of hypercalcemia in hospitalized patients, vitamin D toxicity now represents a significant and preventable contributor in the Kashmiri population. Greater emphasis on rational prescribing, avoidance of high-dose intermittent regimens, and appropriate biochemical monitoring is warranted to reduce iatrogenic hypercalcemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.